EBR Systems (EBR) EGM 2026 summary
Event summary combining transcript, slides, and related documents.
EGM 2026 summary
11 Mar, 2026Opening remarks and agenda
The meeting was opened by the Executive Chairman, confirming a quorum and introducing directors and executives.
The meeting followed the agenda outlined in the notice of meeting dated January 26, 2026.
Specific resolutions to be voted on
Proposal one: Approval of amendments to the Certificate of Incorporation for a reverse stock split at a ratio between 1-for-5 and 1-for-20, at the board's discretion.
Proposal two: Ratification and approval of securities issued in May 2025 under an institutional placement.
Corporate governance
Voting was conducted by poll, with results to be released on the Australian Securities Exchange and the company website.
Only holders of common stock or their proxies could vote online; CDI holders' votes were represented by CHESS Depositary Nominees.
An independent returning officer from Computershare Investor Services was appointed.
Latest events from EBR Systems
- FDA approval and U.S. launch drove $1.6M revenue but net loss reached $48.8M in 2025.EBR
Q4 202520 Mar 2026 - Only FDA-approved, fully leadless CRT device, targeting a $5.8bn US market with rapid growth.EBR
Investor presentation9 Mar 2026 - Shareholders to vote on consolidating common shares for future flexibility; ASX CDIs unaffected.EBR
EGM 202621 Jan 2026 - Leadless left ventricular pacing launches with FDA approval, strong adoption, and $5.8B TAM.EBR
44th Annual J.P. Morgan Healthcare Conference15 Jan 2026 - FDA approval, funding, and commercialization plans defined a pivotal year; key proposals were voted.EBR
AGM 202525 Nov 2025 - Q3 2025 revenue surged 201% sequentially, but net loss increased to $12.2 million.EBR
Q3 2025 TU23 Nov 2025 - FDA approval and first U.S. sales of WiSE CRT System mark a pivotal commercialization milestone.EBR
Q2 2025 TU7 Sep 2025 - Leadless CRT device with pivotal trial success targets US$3.6bn market and FDA approval in 2025.EBR
Investor Presentation30 Jun 2025 - Only leadless CRT device with FDA approval expected by April 2025 and $3.6bn market opportunity.EBR
Investor Presentation30 Jun 2025